Chlortetracycline belongs to the antibiotic class and achieves its selective antibacterial effect by inhibiting a bacterial enzyme or structural component essential for pathogen survival and replication while maintaining a defined safety margin against mammalian cell toxicity. The selectivity index between the antibacterially effective concentration and the mammalian cytotoxic concentration defines the therapeutic window. PDE derivation for Chlortetracycline draws on the critical repeat-dose toxicity study in rodents or higher species, with the NOAEL serving as the point of departure before application of composite uncertainty factors.
Interspecies uncertainty factor F1 refinement for Chlortetracycline is achievable when comparative toxicokinetic data characterise the AUC ratio between humans and the test species at relevant doses, replacing the default allometric scaling assumption.
